Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Boosted by Legacy Private Trust Co.

Legacy Private Trust Co. lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 15.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 6,747 shares of the company’s stock after acquiring an additional 904 shares during the period. Legacy Private Trust Co.’s holdings in Moderna were worth $820,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Norges Bank bought a new position in shares of Moderna during the 4th quarter valued at about $628,359,000. Renaissance Technologies LLC boosted its position in shares of Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after purchasing an additional 1,984,458 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of Moderna by 3.7% during the 1st quarter. Baillie Gifford & Co. now owns 46,466,171 shares of the company’s stock valued at $7,136,275,000 after purchasing an additional 1,679,425 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Moderna by 699.3% during the 1st quarter. Envestnet Asset Management Inc. now owns 1,538,506 shares of the company’s stock valued at $26,205,000 after purchasing an additional 1,346,028 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of Moderna by 19.1% during the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock valued at $752,133,000 after purchasing an additional 670,284 shares in the last quarter. Institutional investors own 64.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Jefferies Financial Group reduced their price objective on shares of Moderna from $275.00 to $175.00 in a research report on Friday, August 4th. Deutsche Bank Aktiengesellschaft lowered shares of Moderna from a “buy” rating to a “hold” rating and reduced their price objective for the company from $200.00 to $125.00 in a research report on Thursday, August 3rd. TD Cowen lowered shares of Moderna from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $145.00 to $125.00 in a research report on Friday, August 4th. Bank of America reduced their price objective on shares of Moderna from $175.00 to $150.00 and set a “neutral” rating for the company in a research note on Friday, August 4th. Finally, Argus reduced their price objective on shares of Moderna from $160.00 to $140.00 and set a “buy” rating for the company in a research note on Wednesday. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $155.52.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $121.95, for a total value of $1,829,250.00. Following the sale, the director now owns 2,127,209 shares in the company, valued at $259,413,137.55. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $121.95, for a total value of $1,829,250.00. Following the completion of the transaction, the director now directly owns 2,127,209 shares of the company’s stock, valued at $259,413,137.55. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Stephen Hoge sold 247 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $102.53, for a total value of $25,324.91. Following the completion of the transaction, the president now directly owns 1,602,579 shares of the company’s stock, valued at $164,312,424.87. The disclosure for this sale can be found here. Insiders have sold a total of 274,209 shares of company stock worth $32,183,061 over the last 90 days. Insiders own 15.70% of the company’s stock.

Moderna Trading Up 1.6 %

Shares of MRNA stock opened at $114.59 on Friday. Moderna, Inc. has a 12 month low of $95.02 and a 12 month high of $217.25. The company has a quick ratio of 3.16, a current ratio of 3.39 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $112.87 and its two-hundred day moving average is $128.06. The company has a market cap of $43.61 billion, a PE ratio of 42.28 and a beta of 1.63.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($3.62) EPS for the quarter, beating the consensus estimate of ($3.84) by $0.22. Moderna had a return on equity of 6.62% and a net margin of 11.33%. The company had revenue of $344.00 million for the quarter, compared to the consensus estimate of $307.67 million. During the same quarter last year, the company posted $5.24 earnings per share. The company’s revenue for the quarter was down 92.8% compared to the same quarter last year. Equities analysts predict that Moderna, Inc. will post -4.31 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.